Gene · 51755
Papers3,441
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 3,441
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Molecular Glues Recruiting RNF213 As an E3 Ligase for Targeted Protein Degradation: A Minimal Dibromoacetamide Warhead As a Recruitment Ligand. | J Am Chem Soc | 2026 | 42336393 | PubTator, text mining | PubMed |
| Prevalence of homologous recombination repair genes alterations in metastatic castration-resistant prostate cancer, a multicentric study. | Fr J Urol | 2026 | 42303208 | PubTator, text mining | PubMed |
| CDK10 loss primes tumor cells for transcriptional vulnerability and sensitizes to CDK12/13 inhibition. | Cell Death Dis | 2026 | 42270604 | PubTator, text mining | PubMed |
| Comprehensive proteogenomic characterization reveals clinically relevant molecular subtypes associated with medulloblastoma progression. | Exp Mol Med | 2026 | 42249086 | PubTator, text mining | PubMed |
| Abemaciclib Inhibits Retinoblastoma Tumor Growth by Targeting CDK1/2. | Invest Ophthalmol Vis Sci | 2026 | 42212883 | PubTator, text mining | PubMed |
| Centralized Homologous Recombination Repair Testing in Metastatic Castration-Resistant Prostate Cancer: Real-World Data from a Multicenter Spanish Precision Oncology Program. | Cancers (Basel) | 2026 | 42192975 | PubTator, text mining | PubMed |
| Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency. | Mol Cancer Ther | 2026 | 42133431 | PubTator, text mining | PubMed |
| Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2. | ESMO Open | 2026 | 42105598 | PubTator, text mining | PubMed |
| Characteristics and therapeutic resistance mechanisms of the prostate cancer immune microenvironment: a comprehensive analysis from bench to clinic. | Front Pharmacol | 2026 | 42022555 | PubTator, text mining | PubMed |
| Corrigendum to "Antitumoral activity of a CDK12 inhibitor in colorectal cancer through a liposomal formulation" [Biomed. Pharmacother. 178 (2024) 117165]. | Biomed Pharmacother | 2026 | 42020214 | PubTator, text mining | PubMed |
| Genetic mutations in salivary duct carcinoma. | Otolaryngol Pol | 2026 | 42003224 | PubTator, text mining | PubMed |
| Phosphosite-centric regulatory network of ATAD2 and its involvement in transcriptional networks. | Mol Genet Genomics | 2026 | 41964706 | PubTator, text mining | PubMed |
| Clinically actionable alterations in Indian breast cancer patients derived through whole transcriptome sequencing. | Indian J Med Res | 2026 | 41934415 | PubTator, text mining | PubMed |
| Differential sensitivity of MCPH1- and BRCA2-deficient cancer cells to PARP-1 inhibition. | PLoS One | 2026 | 41931484 | PubTator, text mining | PubMed |
| Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cells. | Sci Rep | 2026 | 41922714 | PubTator, text mining | PubMed |
| Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy. | JCO Precis Oncol | 2026 | 41911515 | PubTator, text mining | PubMed |
| TONSOKU prevents the formation of large tandem duplications and restrains ATR-WEE1 checkpoint activation. | Nat Commun | 2026 | 41896247 | PubTator, text mining | PubMed |
| Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. | J Cell Mol Med | 2026 | 41896195 | PubTator, text mining | PubMed |
| The transcription elongation factors Spt4 and Spt6 promote dermal adipocyte differentiation. | Adipocyte | 2026 | 41891546 | PubTator, text mining | PubMed |
| Development and validation of a highly accurate multigene gene expression biomarker to predict chemotherapy response in primary triple-negative breast cancer. | Breast Cancer Res Treat | 2026 | 41885969 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51755/papers?page=3